U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07681089) titled 'A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia.' on June 26.
Brief Summary: This is a phase 2 study designed to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Liver Cirrhosis
Intervention:
DRUG: Foscenvivint
Experimental:Foscenvivint Arm Description:Foscenvivint 280 mg/m2, once a week for 24 weeks
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kiminori Kimura, MD
Information provided by (Responsible P...